Join 120+ Experts Including:
Design, Manufacture & Deliver Safer, More Efficacious, Globally Accessible Treatments for Solid Tumors, Leveraging γδT Mechanisms
As newly published data show the first Gamma Delta T cell therapy's clinical efficacy in patients, the race to market for the first allogeneic and solid tumor-targeting γδT has begun.
Join us at the 3rd Gamma Delta T Therapies Summit alongside 120+ of the world’s leaders in the field to discuss discovery to manufacturing and clinical development of these ‘holy grail’ therapies in allogeneic and solid tumor settings.
Developed with key opinion leaders such as Adrian Hayday, and experts from Adicet Bio, Lava Therapeutics, IN8 Bio, and many more, attend this meeting to engage in interactive discussions and gain the actionable insights to advance bench to commercial bedside development of γδT-based therapies.
Gather in person for the very first time with industry pioneers harnessing GDT cells to bring to market more cytotoxic, clinically safe therapies for solid tumors.
From modulating cell activity through genetic engineering and antibody engagement to enhancing the functionality of GDT cells through an improved understanding of their intrinsic biology, this is a conversation you won't want to miss.